Press release
Page 1
H XENON Xenon Pharmaceuticals Provides Updates on Proprietary Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society ( AES 2021 ) December 3 , 2021 -- BURNABY , British Columbia , Dec. 03 , 2021 ( GLOBE NEWSWIRE ) Xenon Pharmaceuticals Inc. ( Nasdaq : XENE ) , a neurology - focused biopharmaceutical company , today announced that it will provide updates on its proprietary , neurology programs at the Annual Meeting of the American Epilepsy Society ( AES 2021 ) . Mr. Ian Mortimer , Xenon's President and Chief Executive Officer stated , " We continue to advance our portfolio of neurology - focused programs , and we have a number of scientific presentations scheduled at the AES 2021 meeting in Chicago . In addition , this year we are hosting a symposium focused on our XEN1101 program and the X - TOLE clinical trial results . We are also participating in a joint industry scientific exhibit related to rare genetically - defined epilepsies , with a particular focus on XEN496 . We are grateful for the opportunity to meet with leading epileptologists , patient advocacy groups , and other key opinion leaders at this important meeting . " The following summarizes Xenon's presentations at AES 2021 related to its proprietary , clinical stage programs as well as promising pre - clinical work : Poster : " Phase 2b Efficacy and Safety of XEN1101 , a Novel Potassium Channel Modulator , in Adults with Focal Epilepsy ( X - TOLE ) " • Please refer to a separate news release also dated today ( December 3 , 2021 ) for a detailed summary of the X - TOLE data and completed sub - analyses that will be presented at AES 2021 . Xenon is hosting a conference call this morning at 9 am ET that will provide an overview of XEN1101 and the Phase 2b X - TOLE study results . Poster : " Electronic Seizure Diary Compliance in an Adult Focal Epilepsy Clinical Trial ” • These data indicate that high eDiary compliance could be maintained in adults with focal onset epilepsy ( FOS ) , aided by central monitoring in real time , potentially setting a new standard for FOS studies . Poster : " XEN1101 , a Differentiated Kv7 Potassium Channel Modulator , Impacts Depression and Anhedonia "